Nuveen LLC Takes $10.34 Million Position in Haemonetics Corporation $HAE

Nuveen LLC bought a new stake in Haemonetics Corporation (NYSE:HAE) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 162,706 shares of the medical instruments supplier’s stock, valued at approximately $10,340,000. Nuveen LLC owned approximately 0.32% of Haemonetics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. TD Waterhouse Canada Inc. purchased a new position in shares of Haemonetics in the fourth quarter valued at approximately $25,000. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Haemonetics in the first quarter valued at approximately $65,000. KBC Group NV lifted its position in shares of Haemonetics by 19.9% in the first quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier’s stock valued at $154,000 after acquiring an additional 401 shares in the last quarter. Vise Technologies Inc. lifted its position in shares of Haemonetics by 8.7% in the fourth quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier’s stock valued at $221,000 after acquiring an additional 225 shares in the last quarter. Finally, CWC Advisors LLC. lifted its position in shares of Haemonetics by 7.4% in the fourth quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier’s stock valued at $241,000 after acquiring an additional 212 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

HAE stock opened at $56.2770 on Friday. The business has a fifty day moving average of $69.50 and a two-hundred day moving average of $66.32. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. The stock has a market cap of $2.71 billion, a price-to-earnings ratio of 17.21, a price-to-earnings-growth ratio of 0.99 and a beta of 0.40. Haemonetics Corporation has a 52-week low of $50.68 and a 52-week high of $94.99.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.09. The company had revenue of $321.39 million during the quarter, compared to analysts’ expectations of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The firm’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, research analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Analysts Set New Price Targets

HAE has been the topic of several research reports. Needham & Company LLC restated a “buy” rating and issued a $68.00 target price (down previously from $84.00) on shares of Haemonetics in a research report on Thursday, August 7th. Raymond James Financial downgraded Haemonetics from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the stock from $105.00 to $78.00 in a research report on Monday, August 11th. Robert W. Baird started coverage on Haemonetics in a research report on Thursday, June 26th. They set an “outperform” rating and a $87.00 price objective on the stock. Mizuho reduced their price objective on Haemonetics from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. Finally, Wall Street Zen downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $85.18.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.